News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases 2016

December 13, 2016
Kyowa Hakko Kirin Announces Top-Line Results of Global Phase 3 Trial of KW-6002 (Istradefylline) for Parkinson's DiseasePDF file:New window opens(90KB)
October 28, 2016
Consolidated Financial Summary Fiscal 2016 Third QuarterPDF file:New window opens(101KB)
October 28, 2016
Appendix to the Consolidated Financial Summary Fiscal 2016 Third QuarterPDF file:New window opens(224KB)
October 28, 2016
Kyowa Hakko Kirin Announces AstraZeneca Has Exercised the Exclusive Option for Commercialization of Benralizumab (KHK4563) in JapanPDF file:New window opens(104KB)
October 26, 2016
Kyowa Hakko Kirin Announces First Patient Enrolled Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia (XLH)PDF file:New window opens(125KB)
October 19, 2016
Fujifilm Kyowa Kirin Biologics Announces Positive Result in Primary Endpoint from Phase 3 Study of Adalimumab Biosimilar, anti-TNF-α Monoclonal AntibodyPDF file:New window opens(99KB)
October 19, 2016
Kyowa Hakko Kirin and BioWa File Suit in the U.S. to Defend Patent Rights on POTELLIGENT® TechnologyPDF file:New window opens(49KB)
September 28, 2016
Application seeking Approval for Additional formulation of ACOALAN® in Japan
September 27, 2016
Launch of LUMICEF® for Psoriasis Treatment, in Japan
September 20, 2016
Kyowa Hakko Kirin Announces Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked HypophosphatemiaPDF file:New window opens(643KB)
September 20, 2016
Kyowa Hakko Kirin Announces Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced OsteomalaciaPDF file:New window opens(517KB)
August 8, 2016
Notice of revision to Appendix to the Consolidated Financial Summary Fiscal 2016 InterimPDF file:New window opens(254KB)
August 8, 2016
Kyowa Hakko Kirin Announced Kyowa Medex Acquired approval for Insurance Coverage of "25-Hydroxyvitamin D Assay"
August 2, 2016
Kyowa Hakko Kirin Completed of Construction for the Biopharmaceutical API Manufacturing Facility in the Takasaki PlantPDF file:New window opens(87KB)
July 29, 2016
Consolidated Financial Summary Fiscal 2016 InterimPDF file:New window opens(113KB)
July 29, 2016
Appendix to the Consolidated Financial Summary Fiscal 2016 InterimPDF file:New window opens(177KB)
July 29, 2016
Results Presentation Fiscal 2016 InterimPDF file:New window opens(2,717KB)
July 21, 2016
Kyowa Hakko Kirin Revises ForecastsPDF file:New window opens(49KB)
July 4, 2016
LUMICEF® approved in JapanPDF file:New window opens(112KB)
June 28, 2016
US Food and Drug Administration Granted Breakthrough Therapy Designation for KRN23 for Pediatric X-Linked HypophosphatemiaPDF file:New window opens(45KB)
June 6, 2016
Kyowa Hakko Kirin Entered into an Agreement with Medgenics for the Clinical Development of anti-LIGHT Monoclonal AntibodyPDF file:New window opens(88KB)
June 6, 2016
Kyowa Hakko Kirin Announces Preliminary Results from Pivotal Phase 2 Study of Mogamulizumab (KW-0761) in Patients with Relapsed or Refractory Adult T-cell Leukemia-LymphomaPDF file:New window opens(50KB)
May 23, 2016
Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal Function by Inulin Clearance in a Phase 2 Clinical Study in JapanPDF file:New window opens(17KB)
May 17, 2016
Top-Line Results from the Benralizumab Phase 3 Programme in Severe AsthmaPDF file:New window opens(54KB)
April 27, 2016
Consolidated Financial Summary Fiscal 2016 First QuarterPDF file:New window opens(100KB)
April 27, 2016
Appendix to the Consolidated Financial Summary Fiscal 2016 First QuarterPDF file:New window opens(1,071KB)
April 21, 2016
Kyowa Hakko Kirin Announces Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced OsteomalaciaPDF file:New window opens(79KB)
April 1, 2016
New window opensBioWa Announces Office Relocation to Princeton, NJ and appointment of New President and CEOPDF file:New window opens(73KB)
March 31, 2016
Matters concerning controlling shareholdersPDF file:New window opens(44KB)
March 24, 2016
Notice regarding allotment of stock acquisition rights
(stock compensation-type stock options)
PDF file:New window opens(43KB)
March 2, 2016
Initiation of Operations for Drug Product Manufacturing Facility in China
March 1, 2016
New window opensProStrakan and AstraZeneca Enter into Agreement for Rights to Moventig® in EuropePDF file:New window opens(237KB)
February 26, 2016
Change of Representative Directors at Kyowa MedexPDF file:New window opens(31KB)
February 26, 2016
Entries Now Publicly Available from the "Commitment to Life" Contest Movie!
Movies show the philosophy of employees across the Kyowa Hakko Kirin Group
February 19, 2016
Notice regarding stock acquisition rights for the purpose of granting stock compensation-type stock optionsPDF file:New window opens(19KB)
February 4, 2016
FY2016-2020 Mid-term Business PlanPDF file:New window opens(1,694KB)
January 29, 2016
Kyowa Hakko Kirin Announces FY2016-2020 Mid-term Business PlanPDF file:New window opens(123KB)
January 29, 2016
Consolidated Financial Summary Fiscal 2015PDF file:New window opens(221KB)
January 29, 2016
Appendix to the Consolidated Financial Summary Fiscal 2015PDF file:New window opens(1,319KB)
January 29, 2016
Results Presentation Fiscal 2015PDF file:New window opens(710KB)
January 29, 2016
Change in the Company Name of Western Pharmaceutical Subsidiaries of Kyowa Hakko KirinPDF file:New window opens(24KB)
January 25, 2016
Kyowa Hakko Kirin Entered an Agreement with Sandoz for Exclusive Marketing Rights of Rituximab biosimilar in Japan
January 13, 2016
Launch of New Website Content "10 Sounds of Life Science"
- Marriage of Music and Life Science -
PDF file:New window opens(5,122KB)
January 11, 2016
New window opensBioWa opens POTELLIGENT® Technology license to customers for creating POTELLIGENT® cell linesPDF file:New window opens(77KB)

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top